News Releases
Prometheus Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
Jan 03, 2023
Prometheus Biosciences, Inc. Announces Pricing of Public Upsized $500 Million Offering of Common Stock
Dec 08, 2022
Prometheus Biosciences, Inc. Announces Proposed Public Offering of Common Stock
Dec 07, 2022
Prometheus Biosciences Announces Positive Results for PRA023 in Both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Studies Enabling Pathway to Both First-in-Class and Best-in-Class Anti-TL1A mAb
Dec 07, 2022
Prometheus Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress
Nov 09, 2022
Prometheus Biosciences to Participate at November Healthcare Conferences
Nov 01, 2022
Prometheus Biosciences Receives FDA Clearance of IND Application for its Second Precision Program, PRA052
Oct 03, 2022
Prometheus Biosciences to Participate at September Healthcare Conferences
Aug 31, 2022
Prometheus Biosciences Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress
Aug 11, 2022
Prometheus Biosciences to Host a Virtual R&D Day for Analysts and Investors on July 26, 2022
Jul 18, 2022
Displaying 1 - 10 of 47